Forbion

📍 Amsterdam, Niederlande
🏷️ vc
Website besuchen ↗
Investitionsthese

Forbion is a global venture capital firm with a focus on advancing groundbreaking biotech innovations and other sustainable solutions that improve the health of people and the planet. They invest in innovative biotech companies across all stages of (bio-) pharmaceutical drug development through their Ventures and Growth strategies. In addition, they leverage their biotech expertise to address planetary health challenges through their BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies. They aim to select impactful investments that will positively affect the health and well-being of people and the planet while meeting financial return objectives. Forbion's investment approach is centered on building and scaling companies around compelling science and clear unmet needs. They actively source, build, and guide life sciences companies, resulting in numerous breakthrough therapies and successful exits. They manage investments across multiple fund strategies targeting different stages of company development, from pre-clinical and early clinical companies to clinical-stage drug development. Forbion operates a joint venture with BioGeneration Ventures (BGV), focusing on seed and early-stage investments, particularly in Benelux and Germany. The firm's commitment extends beyond capital commitments. They provide their portfolio companies with a collaborative and experienced investing team and advisory network, which bring expansive and profound insights into the companies and value building process. Forbion targets category-defining therapeutics and sustainable biotech solutions with global impact.

Investitionsphase
Pre-seed, Seed, Early-stage, Venture, Growth, Clinical Stage

Bevorzugte Reifephase für die erste Finanzierung.

Sektoren & Themen

Biotech, Pharmaceuticals, Human Health, Planetary Health, Food, Agriculture, Materials, Environmental Technologies, Gene Therapy, CNS Diseases, Muscle Diseases

Thematische Schwerpunkte und Zielmarktsegmente von Interesse.

Ticketgröße
€14.160.000 - €18.560.000

Standard-Finanzierungsbetrag pro Runde.

Outreach & Dossier-Analysen

Verifiziertes E-Mail-Muster

[email protected] | [email protected]

Analysen-Scorecard der Investitionsthese

Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...

Verifizierte Partnerkontakte freischalten

Finde verifizierte E-Mail-Vorlagen, direkt von der KI verfasste Outreach-Texte und berechne Übereinstimmungen mit 1 Klick.

Kostenloses Konto erstellen

Dauert weniger als 30 Sekunden · Keine Kreditkarte erforderlich